BackNKGen Biotech- Warrants (01/09/2028) Overview

NKGen Biotech- Warrants (01/09/2028) Current Cash

Track NKGen Biotech- Warrants (01/09/2028)'s current cash ($6K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$6000.00
↓ 97.89% YoYΔ $-278000.00 vs prior year quarter

Peer trimmed avg / median

Loading

NKGen Biotech- Warrants (01/09/2028) Current Cash History

Loading

NKGen Biotech- Warrants (01/09/2028) vs. peers: Current Cash Comparison

Loading

NKGen Biotech- Warrants (01/09/2028) Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

NKGen Biotech- Warrants (01/09/2028) (NKGNW) FAQ

NKGen Biotech- Warrants (01/09/2028)'s current cash stands at $6K as of March 2025. That compares with $280K in the prior-year period — down 97.9% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

NKGen Biotech- Warrants (01/09/2028) reported $6K in current cash versus $280K a year earlier — a 97.9% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $280K in the prior-year period — down 97.9% year over year. Sustained growth in current cash can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how NKGen Biotech- Warrants (01/09/2028)'s current cash evolved across reporting periods, while the comparison chart places NKGNW next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.